Oakbrook Investments LLC Takes Position in Hologic, Inc. (HOLX)

Oakbrook Investments LLC bought a new position in Hologic, Inc. (NASDAQ:HOLX) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 23,440 shares of the medical equipment provider’s stock, valued at approximately $1,134,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc boosted its position in Hologic by 1.1% during the 3rd quarter. Vanguard Group Inc now owns 28,259,273 shares of the medical equipment provider’s stock valued at $1,158,065,000 after purchasing an additional 303,902 shares during the period. Geode Capital Management LLC raised its stake in Hologic by 5.3% during the 4th quarter. Geode Capital Management LLC now owns 3,805,329 shares of the medical equipment provider’s stock valued at $156,146,000 after acquiring an additional 190,788 shares in the last quarter. Northern Trust Corp raised its stake in Hologic by 1.0% during the 4th quarter. Northern Trust Corp now owns 3,206,982 shares of the medical equipment provider’s stock valued at $131,807,000 after acquiring an additional 30,422 shares in the last quarter. FMR LLC raised its stake in Hologic by 4.8% during the 4th quarter. FMR LLC now owns 2,554,691 shares of the medical equipment provider’s stock valued at $104,998,000 after acquiring an additional 116,507 shares in the last quarter. Finally, American Century Companies Inc. bought a new stake in Hologic during the 4th quarter valued at $104,871,000. Institutional investors own 89.91% of the company’s stock.

Several analysts have weighed in on the company. Zacks Investment Research downgraded Hologic from a “buy” rating to a “hold” rating in a research note on Tuesday, April 2nd. Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 target price on shares of Hologic in a research note on Tuesday, April 2nd. BidaskClub downgraded Hologic from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 4th. TheStreet raised Hologic from a “c” rating to a “b” rating in a research note on Monday, March 4th. Finally, ValuEngine raised Hologic from a “hold” rating to a “buy” rating in a research note on Friday, February 15th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $44.62.

HOLX opened at $43.40 on Friday. Hologic, Inc. has a one year low of $35.10 and a one year high of $48.82. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.91 and a current ratio of 1.30. The firm has a market capitalization of $12.64 billion, a PE ratio of 19.12, a PEG ratio of 2.04 and a beta of 0.75.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, January 30th. The medical equipment provider reported $0.58 EPS for the quarter, topping the Zacks’ consensus estimate of $0.57 by $0.01. Hologic had a positive return on equity of 25.59% and a negative net margin of 12.88%. The company had revenue of $830.70 million for the quarter, compared to the consensus estimate of $823.22 million. During the same quarter in the previous year, the business earned $0.55 EPS. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. On average, research analysts forecast that Hologic, Inc. will post 2.41 EPS for the current year.

In other news, Director Sally Crawford sold 12,306 shares of the business’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $47.61, for a total value of $585,888.66. Following the sale, the director now owns 168,886 shares of the company’s stock, valued at approximately $8,040,662.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Benjamin Jordan Cohn sold 6,830 shares of the business’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $46.70, for a total value of $318,961.00. Following the completion of the sale, the insider now directly owns 22,002 shares in the company, valued at approximately $1,027,493.40. The disclosure for this sale can be found here. Insiders sold a total of 23,378 shares of company stock worth $1,105,836 in the last three months. Company insiders own 0.90% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/oakbrook-investments-llc-takes-position-in-hologic-inc-holx.html.

About Hologic

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Further Reading: What is the S&P 500 Index?

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.